Literature DB >> 9052710

Predicting time to nursing home care and death in individuals with Alzheimer disease.

Y Stern1, M X Tang, M S Albert, J Brandt, D M Jacobs, K Bell, K Marder, M Sano, D Devanand, S M Albert, F Bylsma, W Y Tsai.   

Abstract

OBJECTIVE: To develop and validate an approach that uses clinical features that can be determined in a standard patient visit to estimate the length of time before an individual patient with Alzheimer disease (AD) requires care equivalent to nursing home placement or dies.
DESIGN: Prospective cohort study of 236 patients, followed up semiannually for up to 7 years. A second validation cohort of 105 patients was also followed.
SETTING: Three AD research centers. PATIENTS: All patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and had mild dementia at the initial visit. INTERVENTION: Predictive features, ascertained at the initial visit, were sex, duration of illness, age at onset, modified Mini-Mental State Examination (mMMS) score, and the presence or absence of extrapyramidal signs or psychotic features. MAIN OUTCOME MEASURES: (1) Requiring the equivalent of nursing home placement and (2) death.
RESULTS: Prediction algorithms were constructed for the 2 outcomes based on Cox proportional hazard models. For each algorithm, a predictor index is calculated based on the status of each predictive feature at the initial visit. A table that specifies the number of months in which 25%, 50%, and 75% of patients with any specific predictor index value are likely to reach the end point is then consulted. Survival curves for time to need for care equivalent to nursing home placement and for time to death derived from the algorithms for selected predictor indexes fell within the 95% confidence bands of actual survival curves for patients. When the predictor variables from the initial visit for the validation cohort patients were entered into the algorithm, the predicted survival curves for time to death fell within the 95% confidence bands of actual survival curves for the patients.
CONCLUSIONS: The prediction algorithms are a first but promising step toward providing specific prognoses to patients, families, and practitioners. This approach also has clear implications for the design and interpretation of clinical trials in patients with AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052710

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  87 in total

1.  Predictors of mortality in patients with Alzheimer's disease living in nursing homes.

Authors:  G Gambassi; F Landi; K L Lapane; A Sgadari; V Mor; R Bernabei
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

2.  Alzheimer's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

3.  Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Authors:  Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Kristen Migliaccio-Walle; Frances Garfield
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia.

Authors:  YongJoo Rhee; John G Csernansky; Linda L Emanuel; Chang-Gok Chang; Joseph W Shega
Journal:  J Am Geriatr Soc       Date:  2011-09-23       Impact factor: 5.562

Review 5.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

6.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

7.  Estimation and validation of a multiattribute model of Alzheimer disease progression.

Authors:  Eric Stallard; Bruce Kinosian; Arthur S Zbrozek; Anatoliy I Yashin; Henry A Glick; Yaakov Stern
Journal:  Med Decis Making       Date:  2010 Nov-Dec       Impact factor: 2.583

8.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings.

Authors:  Adeline Gallini; Sandrine Andrieu; Julie M Donohue; Naïma Oumouhou; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur Neuropsychopharmacol       Date:  2013-09-17       Impact factor: 4.600

10.  The effects of patient function and dependence on costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.